Cronos Group (TSE:CRON – Get Rating) was upgraded by equities research analysts at Canaccord Genuity Group to a “buy” rating in a report issued on Thursday. The firm presently has a C$5.00 price target on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 27.23% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. Cowen dropped their price target on Cronos Group from C$4.50 to C$4.30 in a research report on Tuesday, July 19th. Cowen cut their price target on Cronos Group to C$4.30 and set a “na” rating for the company in a research note on Tuesday, July 19th. CIBC raised shares of Cronos Group to a “buy” rating in a research note on Wednesday, May 11th. Finally, Jefferies Financial Group raised their target price on shares of Cronos Group from C$3.70 to C$4.30 in a research note on Thursday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of C$5.54.
Cronos Group Stock Up 3.7 %
Shares of TSE:CRON traded up C$0.14 during trading on Thursday, hitting C$3.93. The company’s stock had a trading volume of 193,360 shares, compared to its average volume of 357,469. The company has a market capitalization of C$1.48 billion and a PE ratio of -4.18. The company has a debt-to-equity ratio of 0.70, a quick ratio of 25.11 and a current ratio of 26.42. Cronos Group has a fifty-two week low of C$3.32 and a fifty-two week high of C$9.68. The business has a 50 day moving average price of C$3.82 and a two-hundred day moving average price of C$4.21.
About Cronos Group
Cronos Group Inc operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets.
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
- C3.AI Stock is a Bargain Enterprise Artificial Intelligence Game Changer
- Two High Yield ETF That Can Substitute For Index Funds
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.